Based on 4 analysts offering 12 month price targets for Lineage Cell Therapeutics Inc
Min Forecast
$2.00+96.08%
Avg Forecast
$4.25+316.67%
Max Forecast
$9.00+782.35%
Should I buy or sell LCTX stock?
Based on 4 analysts offering ratings for Lineage Cell Therapeutics Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LCTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LCTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More
Be the first to know when Wall Street analysts revise their LCTX stock forecasts and price targets.
Is Lineage Cell Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 4 Wall Street analysts covering (NYSEMKT: LCTX) stock is to Strong Buy LCTX stock.
Out of 4 analysts, 3 (75%) are recommending LCTX as a Strong Buy, 1 (25%) are recommending LCTX as a Buy, 0 (0%) are recommending LCTX as a Hold, 0 (0%) are recommending LCTX as a Sell, and 0 (0%) are recommending LCTX as a Strong Sell.
According to 4 Wall Street analysts that have issued a 1 year LCTX price target, the average LCTX price target is $4.25, with the highest LCTX stock price forecast at $9.00 and the lowest LCTX stock price forecast at $2.00.
On average, Wall Street analysts predict that Lineage Cell Therapeutics's share price could reach $4.25 by Jun 23, 2026. The average Lineage Cell Therapeutics stock price prediction forecasts a potential upside of 316.67% from the current LCTX share price of $1.02.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.